# DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

> **NCT06384573** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 40 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia
- Alzheimer's Disease, Familial

## Interventions

- **DRUG:** lecanemab

## Key facts

- **NCT ID:** NCT06384573
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06384573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06384573, "DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06384573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*